Daiichi Sankyo Receives Approval for the Use of Inavir® to Prevent Influenza

Tokyo, Japan (December 20, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that it received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate) for the prevention of influenza in both adults and children.

Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan. The drug was originally launched in Japan for treatment of influenza A and B in October 2010.

Daiichi Sankyo has great expectations for the additional influenza prevention indication for Inavir®, which will provide an additional option for the public to protect themselves against the influenza virus and allow Daiichi Sankyo to further contribute to the health of society.

**Product overview**

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Inavir® Dry Powder Inhaler 20mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of approval for partial changes</td>
<td>December 20, 2013</td>
</tr>
<tr>
<td>Indications and usage (additional approval underlined)</td>
<td>Treatment and prevention of influenza A and B viruses</td>
</tr>
</tbody>
</table>
| Dosage and administration (additional approval underlined) | 1. For treatment of the influenza virus  
   Adults: A single inhaled dose of 40 mg of laninamivir octanoate  
   Children: If less than 10 years old, a single inhaled dose of 20 mg of laninamivir octanoate  
   If 10 years old or older, a single inhaled dose of 40 mg.  
   2. For prevention of the influenza virus  
   Adults and children over 10 years of age: Daily single inhaled dosage of 20 mg of laninamivir octanoate for two days |